Innovative Medicines Initiative, Call for Proposal 2013 for Health , Pharmacueticals, Nursing , and Laboratory Medicines in Lesotho- EU Horizon 2020 and FP7 Funding

1. 11/06/2012
2013 7th call - Health theme -
Contact List
Funding
Areas / Sub-Area Topic Topic title Unit Project Officer(s) E-mail
scheme
0. Key strategic cross-cutting Boosting the translation of FP projects' results into
0-1 SBIR-like All
issues innovative applications for health
1.1. HIGH-THROUGHPUT RESEARCH CLOSED
1.2. DETECTION, DIAGNOSIS & Development of imaging technologies for
MONITORING
1.2-1 CP-SME F5 Philippe JEHENSON Philippe.Jehenson@ec.europa.eu
therapeutic interventions in rare diseases
Modelling toxic responses in case studies for
1.3-1 CP-IP F4 Jürgen Büsing Juergen.Buesing@ec.europa.eu
P predictive human safety assessment
I
L
Innovative approaches to address adverse immune
L 1.3-2 reactions to biomedical devices, implants and CP-FP F4 Bernd Rainer Bernd.Rainer@ec.europa.eu
A 1.3. SUITABILITY, SAFETY, EFFICACY transplant tissues
R OF THERAPIES
1.3-3 Safety and efficacy of therapeutics vaccines CP-FP F4 Andreas Holtel Andreas.Holtel@ec.europa.eu
1
Development of alternative in vitro , analytical,
1.3-4 immunochemical, and other test methods for quality CP-FP F4 Andreas Holtel Andreas.Holtel@ec.europa.eu
control of vaccines
Charles.Kessler@ec.europa.eu;
Controlling differentiation and proliferation in human
1.4. INNOVATIVE THERAPIES 1.4-1 CP-FP F4 Kessler,Sautter,Gancberg Juergen.Sautter@ec.europa.eu;
stem cells intended for therapeutic use
David.Gancberg@ec.europa.eu
Functional validation in animal and cellular models of
2.1.1-1 CP-SME F5 Dirk HADRICH Dirk.Hadrich@ec.europa.eu
genetic determinants of diseases and ageing processes
2.1.1. Large scale
2.1.INTEGRATING data gathering
BIOLOGICAL DATA High impact research initiative on metagenomics
AND PROCESSES 2.1.1-2 CP-IP F5 Dirk HADRICH Dirk.Hadrich@ec.europa.eu
for personalised medicine approaches
2.1.2. Systems
CLOSED
Biology
Prospective longitudinal data collection and
patrizia.tosetti@ec.europa.eu,
2.2.1-1 Comparative Effectiveness Research for traumatic CP-IP F2 P. Tosetti & Ph. Cupers
philippe.cupers@ec.europa.eu
brain injury (TBI)
Development of more effective imaging tools for
patrizia.tosetti@ec.europa.eu,
2.2.1-2 diagnosis, monitoring and management of mental CP-FP F2 P. Tosetti & M. Goldammer
mark.goldammer@ec.europa.eu
disorders
2.2.RESEARCH ON 2.2.1. Brain and Paediatric conduct disorders characterised by
philippe.cupers@ec.europa.eu,
THE BRAIN AND related disorders 2.2.1-3 aggressive traits and / or social impairment: from CP-FP F2 Ph. Cupers & S. Weiland
RELATED sigrid.weiland@ec.europa.eu
preclinical research to treatment
DISEASES, HUMAN
DEVELOPMENT Patho-physiology and therapy of epilepsy and patrizia.tosetti@ec.europa.eu,
2.2.1-4 CP-FP F2 P. Tosetti & S. Weiland
AND AGEING epileptiform disorders sigrid.weiland@ec.europa.eu
philippe.cupers@ec.europa.eu,
2.2.1-5 Understanding and coontrolling pain CP-FP F2 Ph. Cupers & M. Goldammer
mark.goldammer@ec.europa.eu
2.2.2. Human
development and CLOSED
ageing
2.3.0 Cross Christian Desaintes, Ole christian.DESAINTES@ec.europa.eu,
2.3.0-1 Innovation in vaccines CP-SME F3
cutting Olesen ole.OLESEN@ec.europa.eu
Drugs and vaccines for infections that have
2.3.1-1 developed or are at the risk of developing significant SBIR-like F3 Arjon Van Hengel Adrianus.VAN-HENGEL@ec.europa.eu
P 2.3.1. Anti-
anti-microbial resistance
I microbial drug
L 2.3. resistance
L
Stratified approaches to antibacterial and/or
TRANSLATIONAL 2.3.1-2 CP-FP F3 Arjon Van Hengel Adrianus.VAN-HENGEL@ec.europa.eu
A antifungal treatment
RESEARCH IN
R MAJOR 2.3.2. HIV/AIDS,
INFECTIOUS CLOSED
TB, Malaria
2 DISEASES
2.3.3. Emerging Clinical management of patients in severe
2.3.3-1 CP-IP F3 Christian Desaintes christian.DESAINTES@ec.europa.eu
epidemics epidemics
Neglected infectious diseases in Central- and
2.3.4-1 CP-FP F3 Ole Olesen ole.OLESEN@ec.europa.eu
2.3.4 Neglected Eastern Europe
diseases
2.3.4-2 Drug development for neglected parasitic diseases CP-SME F3 Ole Olesen ole.OLESEN@ec.europa.eu
Investigator-driven treatment trials to combat 0r jan-willem-van-de-loo@ec.europa.eu,
2.4.1-1 CP-FP F2 J van de Loo, N Trzaska
prevent metastases in patients with solid cancer Dominika.TRZASKA@ec.europa.eu
2.4.1. Cancer jan-willem-van-de-loo@ec.europa.eu,
2.4.1-2 Strengthening the cancer patient's immune system CP-FP F2 J van de Loo, N Trzaska
Dominika.TRZASKA@ec.europa.eu
Investigator-driven supportive and palliative care jan-willem-van-de-loo@ec.europa.eu,
2.4.1-3 CP-FP F2 J van de Loo, N Trzaska
clinical trials and observational studies Dominika.TRZASKA@ec.europa.eu
Discovery research to reveal novel targets for
2.4.2-1 CP-SME F2 V Dambrauskaite Virginija.DAMBRAUSKAITE@ec.europa.eu
2.4.2. cardiovascular disease treatment
2.4.TRANSLATIONA
Cardiovascular
1/2

2. 11/06/2012
2013 7th call - Health theme -
Contact List
Funding
Areas / Sub-Area Topic Topic title Unit Project Officer(s) E-mail
scheme
Cardiovascular
L RESEARCH IN Comparative effectiveness research of existing tools
OTHER MAJOR diseases
2.4.2-2 for prevention, diagnosis and treatment of CP-FP F2 V Dambrauskaite Virginija.DAMBRAUSKAITE@ec.europa.eu
DISEASES cardiovascular diseases
Optimising lifestyle interactions in the prevention and
2.4.2-3 treatment of cardiovascular disease across the CP-FP F2 V Dambrauskaite Virginija.DAMBRAUSKAITE@ec.europa.eu
lifespan
2.4.3. Diabetes
CLOSED
and obesity
2.4.4. Rare
CLOSED
diseases
2.4.5. Other
CLOSED
chronic diseases
3.1. TRANSLATING THE RESULTS OF
Comparative Effectiveness Research (CER) in
CLINICAL RESEARCH OUTCOME INTO 3.1-1 CP-FP F3 Barbara Kerstiens Barbara.KERSTIENS@ec.europa.eu
CLINICAL PRACTICE health systems and health services interventions
3.2. QUALITY, EFFICIENCY AND
P SOLIDARITY OF HEALTHCARE
I SYSTEMS INCLUDING TRANSITIONAL CLOSED
L HEALTH SYSTEMS
L
A
R
3.3. HEALTH PROMOTION AND
PREVENTION
3.3-1 Social innovation for health promotion CP-FP F3 Caroline Attard Caroline.ATTARD@ec.europa.eu
3
3.4. INTERNATIONAL PUBLIC HEALTH &
HEALTH SYSTEMS
Supporting industrial participation in EU-funded
4.1-1 CA F1 Ludovica Serafini Ludovica.serafini@ec.europa.eu
research in the health sector
Interactions between EU legislation and health
4.1-2 SA F1 Joana Namorado joana.namorado@ec.europa.eu
research and/or innovation
4.1-3 Support for Presidency events SA F1 Peter Loffler peter.loffler@ec.europa.eu
4.1. COORDINATION AND SUPPORT
ACTIONS ACROSS THE THEME
Preparing the future for health research and
4.1-4 SA F1 Olivier Le Dour olivier.le-dour@ec.europa.eu
innovation
Global initiative on gene-environment interactions in
diabetes/obesity in specific populations. karim.berkouk@ec.europa.eu,
4,1-5 CA F2 K. Berkouk, N. Vercruysse
nathalie.vercruysse@ec.europa.eu
Mapping chronic non-communicable diseases
4.1-6 CA F2 K. Berkouk karim.berkouk@ec.europa.eu
research activities.
Investigator-driven clinical trials for off-patent
medicines using innovative, age-appropriate
4.2-1 CP-FP F5 Alexandru COSTESCU Alexandru-Sorin.Costescu@ec.europa.eu
formulations and/or delivery systems addressing
one of the options given in the topic description
4.2. RESPONDING TO EU POLICY
NEEDS
4.2-2 Adverse drug reaction research. CP-FP F5 Iiro EEROLA Iiro.Eerola@ec.europa.eu
New methodologies for clinical trials for small F5 Irene NORSTEDT Irene.Norstedt@ec.europa.eu
4.2-3 CP-FP
population groups
2/2